Biomark Diagnostics Inc (OP: BMKDF )

0.1554 UNCHANGED

Last Price Updated: 2:56 PM EST, Nov 21, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	0.1554
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.1554
Today's Range	0.1554 - 0.1554
52wk Range	0.1335 - 0.2300
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

December 29, 2023

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"...

Via Newsfile

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

December 04, 2023

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)...

Via Newsfile

Performance

YTD	-16.14%	-16.14%
1 Month	+3.60%	+3.60%
3 Month	+14.52%	+14.52%
6 Month	+8.67%	+8.67%
1 Year	-19.31%	-19.31%

More News

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

November 28, 2023

Via Newsfile

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

November 14, 2023

Via Newsfile

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

November 07, 2023

Via Newsfile

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

October 24, 2023

Via Newsfile

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

August 30, 2023

Via Newsfile

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

August 08, 2023

Via Newsfile

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

June 05, 2023

Via Newsfile

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

May 31, 2023

Via Newsfile

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

May 03, 2023

Via Newsfile

Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay

April 10, 2023

Via Benzinga

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

March 16, 2023

Via Newsfile

Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring

February 07, 2023

Via Newsfile

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

January 11, 2023

Via Newsfile

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

November 30, 2021

Via Newsfile

Detecting Early Cancer Screening Stocks At An Early Stage Is Critical

November 22, 2021

Via Benzinga

Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021

October 18, 2021

Via Newsfile

A Cryptocurrency, A Big Board Name, And A Penny Stock Look Bullish Going Into The Week

April 18, 2021

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.